Tislelizumab improves overall survival compared to chemotherapy in esophageal squamous cell carcinoma
Tislelizumab (BeiGene, Ltd) improved overall survival (OS) in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) compared to chemotherapy, according to a press release.
Tislelizumab, an anti-PD-1 antibody, was evaluated in the phase 3 RATIONALE 302 trial compared to investigator’s choice chemotherapy in patients with advanced unresectable or metastatic ESCC who have received prior systemic treatment
“Esophageal cancer represents a significant unmet medical need with rapid progression and high mortality. Recent years have seen a paradigm-shift in advanced ESCC treatment from chemotherapy and radiation to immunotherapy. The positive topline results from the RATIONALE 302 trial demonstrated that tislelizumab may offer a new treatment option for those living with this devastating disease and bring hope to patients and their families,” said Lin Shen, MD, Vice President of Clinical Oncology at Beijing Cancer Hospital and lead investigator for the trial, in the press release.
Read the full press release here.
